The Australian Medical Association has welcomed the start of the Therapeutic Goods Administration's (TGA) consultation into unapproved medicinal cannabis products. Following AMA advocacy on the issue, head of the TGA Professor Tony Lawler announced the consultation at the AMA25 national conference earlier this month.
AMA President Dr Danielle McMullen thanked Professor Lawler and the TGA for acting and speaking about the rise in direct-to-consumer telehealth models, where the risks are potentially outweighing the benefits.
The TGA's consultation begins today, and Dr McMullen said the AMA was looking forward to contributing to this important discussion.
"We welcome the opportunity to raise key concerns about unapproved medicinal cannabis products, which are being prescribed at alarming rates through direct-to-consumer telehealth models," Dr McMullen said.
Read more at The National Tribune
